Background and Objectives. e pneumococcal urinary antigen test (UAT) has superior sensitivity to other investigations in determining the aetiology of community-acquired pneumonia (CAP), but data speci�c to Australian populations is limited. is study aimed to establish the prevalence and clinical utility of positive UAT in patients admitted to hospital with CAP, as well as associations with positive testing. Methods. A prospective, cross-sectional, single-centre study was performed. Urine antigen tests were performed on all adult patients admitted to hospital with the diagnosis of CAP. Sputum and blood culture results, CURB-65 score of severity, current and prior antibiotics, comorbidities, mortality, and length of hospital stay were recorded. Results. ere was a positive test prevalence of 13/170 [7.6% (95% con�dence intervals 4.3-13%)]. e overall prevalence of pneumococcal pneumonia was 19/170 (11%), including 8 patients con�rmed on positive UAT alone. Patients with a positive UAT result had a higher mean CURB-65 score compared with those with a negative result ( ), and a greater likelihood of requiring intensive care support ( ). Conclusions. e prevalence of positive UAT was low. Positive results were more oen recorded in those with greater severity pneumonia. e clinical utility of the test in this cohort of patients was low.
Introduction
Community-acquired pneumonia (CAP) is an important and common disease entity, accounting for more than 100 000 hospital admissions in Australia per year [1] . In-hospital mortality can be as high as 20% in certain subgroups of patients admitted with CAP [2] . Increased attributable mortality is also observed beyond the acute episode, particularly in the elderly [3, 4] . Not surprisingly, the economic and disability costs to the community are signi�cant.
Even where extensive and invasive investigations are undertaken in CAP studies, diagnostic yield is oen low, with no causative organism identi�ed in up to 50% of cases. In clinical practice, this yield is even lower. As a result, data on CAP aetiology is imprecise [5] . A lack of diagnostic tests with su�cient sensitivity and speci�city has led to the development of new methods. e S. pneumoniae Urinary Antigen Test (Binax NOW), an immunochromatographic membrane assay that detects the C-polysaccharide antigen in the cell wall of S. pneumoniae, has been in widespread clinical use since 2001 [6] . e test is rapid, simple to perform, and less likely to be in�uenced by prior antibiotic use than sputum and blood cultures. Sensitivity is reportedly 58-100%, and speci�city is 82-100% [6] [7] [8] [9] [10] [11] [12] [13] . Prevalence of positivity appears to vary widely between populations, with �gures of 10-40% cited [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
e pneumococcal urine antigen test (UAT) has been investigated in both immunocompetent and HIV adult patients hospitalized with CAP, with comparable highstandard performance in both populations [6] [7] [8] [9] [10] [11] [12] [13] . Despite its validation as a superior investigation in terms of sensitivity and speci�city compared with more conventional microbiological tests, the role of the pneumococcal UAT in evaluating CAP patients remains uncertain, with no clear consensus on when the test should be performed [5, 17, 18] .
e evidence for a positive result impacting on management is also limited. Guidelines on antibiotics in CAP incorporate therapy to cover S. pneumonia [5, 17, 18] , and increasing data suggest a survival bene�t in empiric strategies that include a macrolide, particularly in those with severe illness [19, 20] . e primary aims of this study were to establish the prevalence of positive pneumococcal UAT in patients requiring hospital admission for CAP, and to determine the utility of the test both in terms of diagnostic yield, and in�uence on management. A secondary aim was to de�ne particular patient characteristics associated with test positivity.
Methods

Design and Patient Population.
We performed a prospective study of all patients (age ≥18 yrs) admitted consecutively to a single centre with community-acquired pneumonia between May 2010 and January 2011. e study was conducted at a 985-bed tertiary teaching hospital in Sydney, Australia, with a local catchment population of 350,000. Human Research Ethics Committee approval was obtained.
A total of one hundred and seventy patients with new diagnosis of CAP were included in the study. Exclusion criteria included aspiration or hospital acquired pneumonia, cystic �brosis, or a subsequent alternative diagnosis to account for the clinical presentation (e.g., Mycobacterium infection, extrinsic allergic alveolitis, or malignancy).
Measurements.
Urine specimens were collected from all patients within the �rst 48 hours of admission. Samples were tested for pneumococcal antigen using the Binax NOW S. pneumoniae urinary antigen test (Binax, Scarborough, ME, USA), in accordance with manufacturer's instructions. Test swabs were dipped into nonconcentrated urine within 2 hours of specimen reception, with results read at 15 minutes. Further microbiological investigations were performed at the discretion of the treating clinician. ese included blood cultures, pleural �uid, sputum, and bronchial alveolar lavage (BAL) samples for Gram stain and culture, urinary antigen testing for Legionella, and paired sera for Chlamydophilia pneumoniae, Mycoplasma pneumonia, and Legionella pneumophila; each performed by conventional methods.
Data on other clinical parameters were also collated, including age, gender, chest radiograph changes, antibiotic use within the 2 weeks prior to admission, length of hospital stay, in-hospital mortality, antibiotic therapy during admission, requirement for intensive care support, CURB-65 scores of pneumonia severity (scoring by confusion, uraemia, respiratory rate, low blood pressure, and age ≥65 years) [21] , tobacco and ethanol use, and comorbid illness. Results of all variables were entered into a computer database.
De�nitions.
CAP was de�ned by new in�ltrates on chest radiograph along with 2 or more consistent clinical features (cough, purulent sputum, fever, pleuritic chest pain, leukocytosis (white blood cell count >10,000/L), or dyspnoea). e diagnosis of pneumococcal pneumonia was considered de�nite or probable if the pathogen was cultured from blood, pleural �uid, or good quality sputum, or if urinary antigen testing was positive. Excessive ethanol consumption was de�ned as >6 standard drinks per day for men and >4 per day for women. Patients were de�ned as immunosuppressed if they were receiving prednisone therapy ≥10 mg/day or equivalent for >3 months, had concurrent malignancy, were treated with systemic chemotherapy, had received solid organ, bone marrow or stem cell transplantation, or had human immunode�ciency virus (HIV) infection. 
Statistical
Results
Urine Antigen Test
Results and Aetiology. All 170 patients admitted to hospital with CAP underwent pneumococcal urine antigen testing (UAT). UAT was positive in 13 patients, giving a positive test prevalence of 7.6% (95% CI 4.3-13%). Overall, a de�nite or probable diagnosis of pneumococcal pneumonia was established in 19 of 170 patients (11%). Characteristics of study participants are described in Table 1 .
Utility of Test.
Of the patients diagnosed with pneumococcal pneumonia, 8 patients had positive UAT alone. ere were 6 patients with positive blood and/or sputum cultures for S. pneumoniae in whom the UAT was negative, as outlined in Table 2 . A positive urine antigen test resulted in modi�cation of initial antibiotic therapy in 5 out of 13 patients (38%). In these cases, patients were changed to either ampicillin or benzylpenicillin monotherapy. e other 8 patients were continued on initial empirical therapy, which included a combination of a penicillin or third-generation cephalosporin with a macrolide. ere was one in-hospital fatality in each group (
. ere was no signi�cant difference in length of hospital stay between those treated empirically and those with pathogen-directed therapy (15.2 versus 8.0 days, ). 
Patient Characteristics associated with
. Patients who tested positive were more likely to have higher CURB-65 severity scores (mean of 2.7, compared with 1.6 in patients with negative results, . 1). Figure 1 demonstrates the spread of CURB-65 scores with respect to UAT result. ere was a greater requirement for intensive care support in patients with positive results ( . 6). ere were also a greater proportion of current smokers in the positive group ( . 49). Abbreviations- † ICU: intensive care unit admission ‡ CURB-65 score: pneumonia severity according to confusion, uraemia, elevated respiratory rate, low blood pressure, and age greater than or equal to 65 years.
Logistic regression was performed to analyse the speci�c factors signi�cantly associated with a positive UAT. e requirement for ICU was not an independent predictor of positivity on multivariate analysis, but severe disease (CURB-65 score >2) and current smoking status demonstrated increased odds ratios of 18.7 (95% CI 4-142) and 6.7 (95% CI 1.8-28.9), respectively. ese results are included in Table 4 .
Discussion
Our study demonstrated a low prevalence of positive pneumococcal urinary antigen tests in Australian patients hospitalised with community-acquired pneumonia. is �nding is contrary to many previously published studies with relatively high rates of positivity. Although numbers were small, there appeared to be a strong correlation between positive results and severe illness, requiring intensive care support, as well as a possible association with current smoking. Even when tests were positive, management was not altered in the majority of cases, with no apparent differences in outcomes.
e reason for disparity between this and previously published studies may partly be related to methodology. Extrapolating previous study results to every-day clinical use is limited by differences between trial methods and routine practice. A number of studies have evaluated concentrated urine specimens with corresponding high yield [6, 7, 10, 12, 14, 22] . Although sensitivity improves with such an approach, the cost is a greater likelihood of false-positive results. Current clinical practice, following manufacturer's instructions, is to analyse nonconcentrated urine to establish the presence of antigen. Variations in local epidemiology are also likely to in�uence the �ndings. Studies of UAT in hospitalized CAP patients from Europe, Asia, and New Zealand have demonstrated positivity rates of 28-39% [6] [7] [8] [9] [10] [11] [12] [13] . e large prospective Australian epidemiologic study of CAP aetiology, published by Charles et al. in 2008 had a signi�cantly lower rate of only 11.2% of positive UAT. ere was also a low overall prevalence of pneumococcal pneumonia, with only 14% of cases attributed to this organism [16] . A Spanish retrospective analysis including over four hundred thousand hospitalized CAP patients over 5 years showed pneumococcus to be the causative agent in 17% [23] . e difference between these recent studies and previously reported rates of 30-50% is striking and cannot fully be explained by the previous employment of invasive investigations no longer in use [24, 25] . e declining incidence of pneumococcal pneumonia may be a phenomenon related to increasing rates of vaccination against S. pneumoniae as well as patterns of antibiotic use in the community, but the explanation remains unclear at this stage.
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Our study, demonstrating a prevalence of positive pneumococcal UAT in only 7.6%, is possibly re�ective of both reallife practice and local pneumonia aetiology. Although this study did not incorporate extensive diagnostic evaluation in all participants beyond the UAT, it is interesting to note our comparable rates of pneumococcal pneumonia with the more de�nitive aetiologic study by Charles et al. �11 versus 14%) [16] . We cannot, however, draw speci�c conclusions about the rate of pneumococcal infection from our data, given that this was not a study of CAP aetiology.
Our research revealed a number of patient characteristics associated with a greater likelihood of testing positive for pneumococcal antigen. Increasing disease severity, as measured by CURB-65 score, was a predictor for positive UAT. e relationship between severe illness and positive testing may be explained by a higher antigen burden, as suggested by previous studies in bacteraemic patients [6, 10, 12, 14] . Current smoking was another signi�cant predictor for positive UAT. is is consistent with the previous observation that tobacco use is strongly associated with pneumococcal infection, and in particular, with invasive disease [26, 27] . Other established risk factors for pneumococcal disease, including alcoholism, immunosuppression, diabetes mellitus, underlying lung disease, and advancing age [28] were not predictors for UAT positivity in this study.
ere are a number of limitations in this study. With a low prevalence of positivity, the associations with particular patient characteristics had wide con�dence intervals. ese inferences might have been strengthened by recruitment of increased patient numbers across a number of testing centres over a longer trial period. Although this study included all patients admitted under the respiratory service with CAP, there were subgroups of patients that were potentially missed. Very elderly patients with multiple comorbidities presenting with CAP would oen be cared for by the geriatric service, and as such, may have been underrepresented in this cohort.
In conclusion, the present study demonstrates a low diagnostic utility of pneumococcal urine antigen testing when applied in general CAP populations in Australia. e test appears to be most useful in the setting of severe pneumonia, as determined by a high CURB-65 score or the need for admission to the intensive care unit. e test might also have higher yield in patients who are current smokers. Its in�uence on clinical management appears to be diminished by the current widespread evidence-based practice of treating community acquired pneumonia with empirical therapy to cover pneumococcus, along with macrolide antibiotics. is study would suggest a limited role for pneumococcal UAT in diagnostic algorithms for the management of CAP. �on��ct of �nterests e authors declare they have no con�ict of interests.
